1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com


News Release

Contact:
Patricia A. Spinella, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369

BD ANNOUNCES RESULTS FOR FIRST FISCAL QUARTER

First-quarter earnings per share from continuing operations, excluding specified item, increased 11% to $1.07
Raises guidance for full fiscal year 2008 earnings per share from continuing operations, excluding specified items, to a range of 11% to 13% from 10% to 12%

Franklin Lakes, NJ (January 24, 2008) – BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of $1.706 billion for the first fiscal quarter ended December 31, 2007, representing an increase of 14 percent over the prior year period. This quarter’s growth rate reflects the favorable impact on all segments from foreign currency translation, which overall is estimated to account for 6 percentage points of the growth.

“We are pleased with our strong start to fiscal 2008. Our BD Diagnostics and BD Biosciences segments led our revenue growth,” said Edward J. Ludwig, Chairman, President and Chief Executive Officer. “Disciplined expense management enables us to offset the challenges of raw material price increases and manufacturing start-up costs related to increasing capacity to meet growing demand.”

Analysis of First Quarter Fiscal Year 2008 and 2007 Earnings
The following analysis (Table 1) of diluted earnings per share from continuing operations for the first quarters of fiscal 2008 and 2007 identifies the specified item that affects comparability of results between periods. As illustrated, diluted earnings per share from continuing operations of $1.07 for the first fiscal quarter of 2008 increased by 11 percent over diluted earnings per share from continuing operations, excluding specified item, of 96 cents for the first fiscal quarter of 2007.

(Table 1)	Three Months Ended December 31,
		FY2008		FY2007	% Change

Diluted EPS from Continuing Operations:	$	1.07	$	0.51	110	%

Specified Item:
In-Process Research and Development Charge⁽¹⁾		-		0.45

Diluted EPS from Continuing Operations
Excluding Specified Item:	$	1.07	$	0.96	11	%

⁽¹⁾Represents the effect on diluted earnings per share from continuing operations of the in-process research and development charge recorded in the first quarter of fiscal 2007 related to the TriPath acquisition.

Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $909 million, representing an increase of 10 percent over the prior year period. Pharmaceutical Systems and Diabetes Care products led revenue growth in the segment.

In the BD Diagnostics segment, worldwide revenues for the quarter were $523 million, representing an increase of 18 percent over the prior year period. Five percentage points of this growth is attributable to TriPath, which was acquired near the end of the first fiscal quarter of 2007. Sales of safety-engineered devices and molecular testing systems, including GeneOhm, also contributed to growth.

In the BD Biosciences segment, worldwide revenues for the quarter were $274 million, representing an increase of 18 percent over the prior year period. Demand for research instruments as well as clinical and research reagents continued to be the primary growth drivers.

Geographic Results
First quarter revenues in the U.S. were $790 million, representing an increase of 10 percent over the prior year period. Revenues outside the U.S. were $916 million, representing an increase of 17 percent over the prior year period, and reflect an estimated 11 percent favorable impact from foreign currency translation.

Fiscal 2008 Outlook for Full Year
The Company estimates that diluted earnings per share from continuing operations for the full fiscal year 2008 will increase approximately 11 to 13 percent over diluted earnings per share from continuing operations, excluding the 48 cents in-process research and development charge related to the TriPath and Plasso acquisitions, of $3.84 for the fiscal year 2007.

Conference Call Information
A conference call regarding BD’s first quarter results and its expectations for the full fiscal year will be broadcast live on BD’s website, www.bd.com/investors, at 10:00 a.m. (ET) Thursday, January 24, 2008. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 1-800-475-6701 (domestic) and 1-320-365-3844 (international) through the close of business on January 31, 2008.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and the attached financial tables.

About BD
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

***

This press release, including the section entitled “Fiscal 2008 Outlook for Full Year,” contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)


	Three Months Ended December 31,
	2007		2006		% Change

REVENUES	$	1,705,767	$	1,501,526	13.6

Cost of products sold		829,846		708,933	17.1
Selling and administrative		421,718		384,084	9.8
Research and development		91,527		79,940	14.5
Acquired in-process research and development		-		114,739	NM
TOTAL OPERATING COSTS
AND EXPENSES		1,343,091		1,287,696	4.3

OPERATING INCOME		362,676		213,830	69.6

Interest income		13,528		16,114	(16.0)
Interest expense		(10,339)		(12,868)	(19.7)
Other income (expense), net		707		(2,368)	NM

INCOME FROM CONTINUING OPERATIONS BEFORE
INCOME TAXES		366,572		214,708	70.7

Income tax provision		95,676		83,657	14.4

INCOME FROM CONTINUING OPERATIONS		270,896		131,051	NM

INCOME FROM DISCONTINUED OPERATIONS
NET OF INCOME TAX PROVISION OF
$386 AND $7,140, RESPECTIVELY		652		11,828	(94.5)

NET INCOME	$	271,548	$	142,879	90.1

EARNINGS PER SHARE

Basic:
Income from continuing operations	$	1.11	$	0.53	NM
Income from discontinued operations	$	-	$	0.05	NM
Net income	$	1.11	$	0.58	91.4

Diluted:
Income from continuing operations	$	1.07	$	0.51	NM
Income from discontinued operations	$	-	$	0.05	NM
Net income	$	1.07	$	0.56	91.1

AVERAGE SHARES OUTSTANDING

Basic		244,292		245,550
Diluted		253,116		254,941

NM - Not Meaningful

Page 1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
(Unaudited; Amounts in thousands, except per share data)


	Three Months Ended December 31, 2006
	As		TriPath		Excluding
	Reported		IPR&D (1)		Items

Operating Income	$	213,830	$	114,739	$	328,569
as a % of revenues		14.2%				21.9%

Income taxes		83,657		-		83,657
effective tax rate		39.0%				25.4%

Income from continuing operations		131,051		114,739		245,790
as a % of revenues		8.7%				16.4%

Diluted earnings per share
Income from continuing operations	$	0.51	$	0.45	$	0.96

(1) Represents the acquired in-process research and development charge of $114,739 related to the TriPath acquisition.


	Fiscal Year 2007
	As				Excluding
	Reported		IPR&D (2)		Items

Diluted earnings per share
Income from continuing operations	$	3.36	$	0.48	$	3.84

(2) Represents the acquired in-process research and development charges related to the TriPath and Plasso acquisitions.

Page 2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)


	Three Months Ended December 31,
		2007		2006	% Change

BD MEDICAL
United States	$	407,491	$	381,806	6.7
International		501,793		444,441	12.9
TOTAL	$	909,284	$	826,247	10.0

BD DIAGNOSTICS
United States	$	279,488	$	242,899	15.1
International		243,263		199,501	21.9
TOTAL	$	522,751	$	442,400	18.2

BD BIOSCIENCES
United States	$	103,071	$	95,921	7.5
International		170,661		136,958	24.6
TOTAL	$	273,732	$	232,879	17.5

TOTAL REVENUES
United States	$	790,050	$	720,626	9.6
International		915,717		780,900	17.3
TOTAL	$	1,705,767	$	1,501,526	13.6

Page 3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31,
(Unaudited; Amounts in thousands)


	United States
	2007		2006		% Change

BD MEDICAL
Medical Surgical Systems	$	252,745	$	242,301	4.3
Diabetes Care		98,526		90,492	8.9
Pharmaceutical Systems		49,978		42,899	16.5
Ophthalmic Systems		6,242		6,114	2.1
TOTAL	$	407,491	$	381,806	6.7

BD DIAGNOSTICS
Preanalytical Systems	$	143,300	$	131,703	8.8
Diagnostic Systems		136,188		111,196	22.5
TOTAL	$	279,488	$	242,899	15.1

BD BIOSCIENCES
Cell Analysis (1)	$	67,358	$	61,833	8.9
Discovery Labware		35,713		34,088	4.8
TOTAL	$	103,071	$	95,921	7.5

TOTAL UNITED STATES	$	790,050	$	720,626	9.6

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

Page 4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31, (continued)
(Unaudited; Amounts in thousands)


	International
					% Change
	2007		2006		Reported	FX Neutral	FX Impact

BD MEDICAL
Medical Surgical Systems	$	246,066	$	225,450	9.1	(0.4)	9.5
Diabetes Care		90,861		78,194	16.2	5.2	11.0
Pharmaceutical Systems		151,963		130,041	16.9	4.7	12.2
Ophthalmic Systems		12,903		10,756	20.0	8.3	11.7
TOTAL	$	501,793	$	444,441	12.9	2.3	10.6

BD DIAGNOSTICS
Preanalytical Systems	$	128,169	$	108,369	18.3	6.9	11.4
Diagnostic Systems		115,094		91,132	26.3	15.9	10.4
TOTAL	$	243,263	$	199,501	21.9	11.0	10.9

BD BIOSCIENCES
Cell Analysis (1)	$	137,755	$	107,158	28.6	26.3	2.3
Discovery Labware		32,906		29,800	10.4	0.7	9.7
TOTAL	$	170,661	$	136,958	24.6	13.9	10.7

TOTAL INTERNATIONAL	$	915,717	$	780,900	17.3	6.5	10.8

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

Page 5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31, (continued)
(Unaudited; Amounts in thousands)


	Total
					% Change
		2007		2006	Reported	FX Neutral	FX Impact

BD MEDICAL
Medical Surgical Systems	$	498,811	$	467,751	6.6	2.0	4.6
Diabetes Care		189,387		168,686	12.3	7.2	5.1
Pharmaceutical Systems		201,941		172,940	16.8	7.6	9.2
Ophthalmic Systems		19,145		16,870	13.5	6.0	7.5
TOTAL	$	909,284	$	826,247	10.0	4.3	5.7

BD DIAGNOSTICS
Preanalytical Systems	$	271,469	$	240,072	13.1	8.0	5.1
Diagnostic Systems		251,282		202,328	24.2	19.5	4.7
TOTAL	$	522,751	$	442,400	18.2	13.2	5.0

BD BIOSCIENCES
Cell Analysis (1)	$	205,113	$	168,991	21.4	19.9	1.5
Discovery Labware		68,619		63,888	7.4	2.9	4.5
TOTAL	$	273,732	$	232,879	17.5	11.2	6.3

TOTAL REVENUES	$	1,705,767	$	1,501,526	13.6	8.0	5.6

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

Page 6